Lumito AB has entered into an agreement with Mangold Fondkommission AB to act as the company's mentor in trading on NGM Nordic SME. Mangold Fondkommission will take over as mentor for the company on 15 October 2021. Lumito has simultaneously terminated the agreement with G&W Fondkommission AB, which expired on 14 October 2021.
For further information, please contact:
Lumito's CEO, Mattias Lundin,
e-mail: email@example.com, tel: 076-868 45 09
Please also visit our website.
Lumito specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology.
Lumito's share is traded under the ticker LUMITO on the Nordic Growth Market, NGM SME, where the Company's mentor is Mangold Fondkommission, telephone: +468-503 015 50.